Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MRK NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$85.43-2.2%$81.73$73.31▼$120.30$218.23B0.3812.24 million shs9.25 million shsTRVITrevi Therapeutics$7.28-3.6%$6.81$2.36▼$8.11$919.42M0.581.40 million shs1.22 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.-2.01%+1.45%+0.72%+10.23%-26.73%TRVITrevi Therapeutics-3.58%-2.28%-7.50%+18.18%+143.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRKMerck & Co., Inc.4.9977 of 5 stars3.25.05.04.23.01.73.8TRVITrevi Therapeutics2.8562 of 5 stars4.61.00.00.02.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRKMerck & Co., Inc. 2.35Hold$107.4425.76% UpsideTRVITrevi Therapeutics 3.20Buy$20.11176.25% UpsideCurrent Analyst Ratings BreakdownLatest MRK and TRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025TRVITrevi TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$18.008/8/2025TRVITrevi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetStrong-Buy ➝ Strong-Buy$29.00 ➝ $27.008/8/2025TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $22.007/30/2025MRKMerck & Co., Inc.Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$97.00 ➝ $90.007/10/2025MRKMerck & Co., Inc.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$99.00 ➝ $98.007/1/2025TRVITrevi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.006/2/2025TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/2/2025TRVITrevi TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.005/28/2025TRVITrevi TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$21.00(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRKMerck & Co., Inc.$64.17B3.33$9.26 per share9.23$18.33 per share4.66TRVITrevi TherapeuticsN/AN/AN/AN/A$1.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRKMerck & Co., Inc.$17.12B$6.4913.168.630.9225.79%41.05%16.55%10/30/2025 (Estimated)TRVITrevi Therapeutics-$47.91M-$0.42N/AN/AN/AN/A-41.44%-38.21%11/5/2025 (Estimated)Latest MRK and TRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025TRVITrevi Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A7/29/2025Q2 2025MRKMerck & Co., Inc.$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRKMerck & Co., Inc.$3.243.79%N/A49.92%14 YearsTRVITrevi TherapeuticsN/AN/AN/AN/AN/ALatest MRK and TRVI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/22/2025MRKMerck & Co., Inc.quarterly$0.813.97%9/15/20259/15/202510/7/20255/27/2025MRKMerck & Co., Inc.quarterly$0.814.18%6/16/20256/16/20257/8/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRKMerck & Co., Inc.0.691.421.17TRVITrevi TherapeuticsN/A22.4222.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRKMerck & Co., Inc.76.07%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipMRKMerck & Co., Inc.0.09%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRKMerck & Co., Inc.75,0002.50 billion2.50 billionOptionableTRVITrevi Therapeutics20121.78 million99.49 millionOptionableMRK and TRVI HeadlinesRecent News About These CompaniesTrevi Therapeutics (NASDAQ:TRVI) Now Covered by Morgan StanleyAugust 24 at 2:45 AM | americanbankingnews.comTrevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at Morgan StanleyAugust 23 at 8:13 AM | marketbeat.comMorgan Stanley Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight RecommendationAugust 22, 2025 | msn.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $20.38 Average Price Target from AnalystsAugust 20, 2025 | americanbankingnews.comB. Riley Boosts Earnings Estimates for Trevi TherapeuticsAugust 19, 2025 | marketbeat.comB. Riley Increases Earnings Estimates for Trevi TherapeuticsAugust 19, 2025 | americanbankingnews.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by XTX Topco LtdAugust 17, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from AnalystsAugust 16, 2025 | marketbeat.comPersistent Asset Partners Ltd Makes New $260,000 Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)August 13, 2025 | marketbeat.comInformed Momentum Co LLC Invests $3.47 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)August 13, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), DENTSPLY SIRONA (XRAY) and Arrowhead Pharmaceuticals (ARWR)August 13, 2025 | theglobeandmail.comTrevi Therapeutics: Optimism Amid Earnings Call InsightsAugust 13, 2025 | msn.comHC Wainwright Analysts Increase Earnings Estimates for TRVIAugust 12, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPSAugust 11, 2025 | marketbeat.comRaymond James Financial Issues Pessimistic Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock PriceAugust 10, 2025 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth PlansAugust 10, 2025 | finance.yahoo.comNeedham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $22.00August 9, 2025 | marketbeat.comTrevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comTrevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 7, 2025 | prnewswire.com41,987 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Bought by BIT Capital GmbHAugust 4, 2025 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Up 6,352.7% in JulyAugust 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRK and TRVI Company DescriptionsMerck & Co., Inc. NYSE:MRK$85.43 -1.94 (-2.22%) Closing price 08/25/2025 03:59 PM EasternExtended Trading$85.38 -0.05 (-0.06%) As of 08/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Trevi Therapeutics NASDAQ:TRVI$7.28 -0.27 (-3.58%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$7.28 +0.00 (+0.07%) As of 08/25/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Why Sprouts Farmers Market is Buying $1 Billion of Its Own Stock Time for Cleveland-Cliffs Stock to Break Out? Markets Say Yes Super Micro Computer Stock Hasn't Priced in Growth Yet Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access